PharmaVOICE - 
September 2010
Purchase Issue

In Every Issue
Last Word
USING MONOCLONAL ANTIBODIES What are the opportunities for using monoclonal [...]
By
Talent Pool
Pharmaceutical POOL Lonnel COATS Eisai Names CEO for U.S. Subsidiary [...]
By
E-Media
New Electronic and Web-based Applications, Sites, and Technologies Featured Briefs: [...]
By
PharmaTrax
Sales, Marketing, and R&D Trends from Industry Analysts Featured Briefs: [...]
By
What’s New
Barnett Educational Services has announced the release of updated editions [...]
By
UpFront
Chandler Chicco Co-Founder Receives SABRE Award Bob Chandler, principal and [...]
By
Letter from the Editor
Publisher Lisa Banket Editor Taren Grom Creative Director Marah Walsh [...]
By

Taren Grom, Editor

On The Cover

Comparative Effectiveness: Real-World Evidence of Outcomes
Comparative effectiveness research is going to have a huge impact on every stakeholder in healthcare delivery. It requires a much broader view of the healthcare system so that information will exist about a patient’s outcome as he or she moves from diagnosis to treatment in the healthcare system. Comparative effectiveness data are geared broadly to [...]
By

Denise Myshko

Features

Comparative Effectiveness Research — Watch and Worry or Weigh In and Leverage?
A little-publicized provision of the American Recovery and Reinvestment Act of 2009 is likely to have at least as big, if not a bigger, long-term impact on the pharmaceutical and medical device business as the recently passed Affordable Care Act. This provision allocated .1 billion for comparative effectiveness research (CER) — a mode of research [...]
By

Dr. Ramana Yalamanchili, Mary Anderson, and Michael Zilligen, Ogilvy CommonHealth

View on Med Ed: Refining the Formula
Amid public protests from high-profile figures such as former AHA President Clyde Yancy, M.D., and National Institutes of Health Director Francis Collins, M.D., Ph.D., in June the Accreditation Council for Continuing Medical Education (ACCME) provided additional guidance to its 2004 Standards for Commercial Support related to the role of ACCME-defined commercial interest employees in ACCME-accredited [...]
By

Carolyn Gretton

SHOWCASE FEATURE: No Longer Lost in Translation
As drug development continues to become more of a global endeavor, it’s more important than ever to ensure that documents, especially informed consent and other patient materials, are correctly translated into local languages to ensure the success of the trial. The increasing number of trials, as well as the need for treatment-naïve patients, is forcing [...]
By
DIA Recap
DIA editor’s Choice Videos BBK Joan F. Bachenheimer and Matthew Stum Bioclinica Peter Benton Cognizant Nagaraja Srivatsan Cytel Irving Dark i3 Research Dr. Tracy Tsuetaki INC Research Alistair Macdonald Integrated Clinical Solutions Inc. J. Peter Armerding Kendle Ken Hintze, Ph.D. Kendle Drew Kilpatrick, Ph.D. Kforce Mark Lanfear MediciGlobal Elizabeth Moench Medidata Solutions ­Worldwide Glen de [...]
By
Dr. Leon Smith — Age of Excellence
Imagine an active and comfortable ­retirement, pursuing your hobbies at will and taking time to enjoy the golden years. Sound like fun? Not to Leon Smith, M.D., it ­doesn’t. After almost 55 years as a practicing physician, Dr. Smith is every bit as enthralled and impassioned about being a doctor as he was as a [...]
By

Kim Ribbink

Nichebusters vs.Blockbusters
Transformation in the industry is everywhere, driven by healthcare reform, increased regulatory scrutiny, patent expiry cliffs, and thinning pipelines. The old ways of doing anything — drug development, drug research, sales, marketing, launch activities, market research — are no longer effective and need serious revamping. Enter the nichebuster model — a business paradigm that involves [...]
By

Robin Robinson

Midlevel Healthcare Providers: An Untapped Prescribing Force
Billions of prescriptions — and millions of dollars — are being influenced by a group of individuals who go largely untapped when it comes to communications, outreach, and education. Nurse practitioners (NPs) and physician assistants (PAs) wrote 7.8% of U.S. prescriptions — 308 million from June 2009 through June 2010 — up 20.24% from the [...]
By

Denise Myshko

FEEDBACK